News
LTGO
14.04
-3.64%
-0.53
Weekly Report: what happened at LTGO last week (1026-1030)?
Weekly Report · 2d ago
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 6d ago
'Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying' - NY Times
Benzinga · 10/28 11:29
Weekly Report: what happened at LTGO last week (1019-1023)?
Weekly Report · 10/26 10:34
Weekly Report: what happened at LTGO last week (1012-1016)?
Weekly Report · 10/19 10:34
Weekly Report: what happened at LTGO last week (1005-1009)?
Weekly Report · 10/12 10:41
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
Seeking Alpha · 10/11 20:31
Weekly Report: what happened at LTGO last week (0928-1002)?
Weekly Report · 10/05 10:40
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Seeking Alpha · 10/02 14:15
Weekly Report: what happened at LTGO last week (0921-0925)?
Weekly Report · 09/28 10:34
Weekly Report: what happened at LTGO last week (0914-0918)?
Weekly Report · 09/21 10:35
Weekly Report: what happened at LTGO last week (0907-0911)?
Weekly Report · 09/14 10:41
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks · 09/08 10:01
Weekly Report: what happened at LTGO last week (0831-0904)?
Weekly Report · 09/07 10:33
Primary Markets Group August IPO Update
Seeking Alpha · 09/05 06:30
Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY
Benzinga · 09/03 21:04
*Latigo: Cash and Cash Equivalents Projected to Fund Operating Plans Into 2029 >LTGO
Dow Jones · 09/03 20:19
*Latigo Biotherapeutics 2Q Loss $25.8M >LTGO
Dow Jones · 09/03 20:19
*Latigo Biotherapeutics 2Q Loss/Shr $27.59 >LTGO
Dow Jones · 09/03 20:19
Latigo Biotherapeutics, Inc. reports Q2 results
Seeking Alpha · 09/03 20:17
More
Webull provides a variety of real-time LTGO stock news. You can receive the latest news about Latigo Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its two product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. It is also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches. The Company's lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is its next-generation candidate for the inhibition of Nav1.8, being developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis (OA). LTG-001 and LTG-321 are in clinical development, and LTG-418 and the Company's other product candidates and programs are in preclinical development or discovery stages.